IL33 and type 2 diabetes mellitus: Antibody-mediated systemic inhibition of IL-33 signaling in T2D mice with reduced kidney function and proteinuria (db/db unx) was then sufficient to reduce endothelial inflammation, improve glomerular health, and attenuate overall kidney disease progression.